Our mission is to make biology easier to engineer. Ginkgo is constructing, editing, and redesigning the living world in order to answer the globe’s growing challenges in health, energy, food, materials, and more. Our bioengineers make use of an in-house automated foundry for designing and building new organisms.
Position Summary
We are seeking an experienced Senior Scientist to lead efforts in antibody discovery and developability characterization. This individual will play a critical role in advancing our antibody discovery, production, and characterization platform by applying state-of-the-art biophysical and functional assays to assess antibody properties. The ideal candidate will bring expertise in antibody engineering, developability assessments, and lead selection strategies.
Key Responsibilities
-
Lead method development and execution of antibody production and characterization workflows to support platform programs.
-
Design, develop, and execute biophysical and functional assays to evaluate antibody binding, stability, and activity across a range of assays, for various antibody formats (IgGs, Vhh, minibinders, Fabs, bi- and multi-specifics, etc).
-
Conduct in-depth developability assessments including binding kinetics, thermal/colloidal stability, polyreactivity, aggregation propensity, etc.
-
Support the onboarding of any relevant assays to automated high-throughput platforms.
-
Provide technical leadership in antibody engineering, affinity maturation, and optimization strategies.
-
Mentor junior scientists and contribute to scientific strategy and innovation.
-
Author technical reports, SOPs, and present findings to internal leadership and external customers
Required Qualifications
-
Ph.D. in Biochemistry, Immunology, Bioengineering, or a related field with 2+ years of industry experience in antibody discovery and characterization (or M.S. with 6+ years of industry experience).
-
Expertise in antibody engineering, production (transfection and purification), and developability characterization using biophysical and biological techniques.
-
Extensive hands-on expertise with SPR and BLI for quantitative antibody-antigen interaction analysis
-
Demonstrated proficiency in antibody developability assessment using multiple biophysical techniques (DSF, DLS, SEC, HIC, AC-SINS, Polyreactivity, etc.)
-
Proven ability to lead projects and mentor junior scientists in an industry setting.
-
Excellent communication skills and ability to work in a multidisciplinary environment.
Preferred Qualifications
-
Industry experience in therapeutic antibody discovery and development.
-
Experience in discovery, production and characterization of bi- and multi-specifics
-
Familiarity with automation and high-throughput screening techniques.
-
Knowledge of antibody display platform is desirable
To learn more about Ginkgo, visit www.ginkgobioworks.com/press/ or check out some curated press below:
- What is it really like to take your company public via a SPAC? One Boston biotech shares its journey (Fortune)
- Ginkgo Bioworks resizes the definition of going big in biotech, raising $2.5B in a record SPAC deal that weighs in with a whopping $15B-plus valuation (Endpoints News)
- Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ (CNBC)
- Ginkgo raises $70 million to ramp up COVID-19 testing for employers, universities (Boston Globe)
- Ginkgo Bioworks Redirects Its Biotech Platform to Coronavirus (Wall Street Journal)
- Ginkgo Bioworks Provides Support on Process Optimization to Moderna for COVID-19 Response (PRNewswire)
- The Life Factory: Synthetic Organisms From This $1.4 Billion Startup Will Revolutionize Manufacturing (Forbes)
- Synthetic Bio Pioneer Ginkgo Raises $290 Million in New Funding (Bloomberg)
- Ginkgo Bioworks raises $350 million fund for biotech spinouts (Reuters)
- Can This Company Convince You to Love GMOs? (The Atlantic)
We also feel that it’s important to point out the obvious here – there’s a serious lack of diversity in our industry, and that needs to change. Our goal is to help drive that change. Ginkgo is deeply committed to diversity, equity, and inclusion in all of its practices, especially when it comes to growing our team. Our culture promotes inclusion and embraces how rewarding it is to work with people from all walks of life.
We’re developing a powerful biological engineering platform, so we must remain mindful of the many ways our technology can – and will – impact people around the world. We care about how our platform is used, and having a diverse team to build it gives us the best chance that it’s something we’ll be proud of as it continues to grow. Therefore, it’s critical that we incorporate the diverse voices and visions of all those who play a role in the future of biology.
It is the policy of Ginkgo Bioworks to provide equal employment opportunities to all employees, employment applicants, and EOE disability/vet.
Privacy Notice
I understand that I am applying for employment with Ginkgo Bioworks and am being asked to provide information in connection with my application. I further understand that Ginkgo gathers this information through a third-party service provider and that Ginkgo may also use other service providers to assist in the application process. Ginkgo may share my information with such third-party service providers in connection with my application and for the start of employment. Ginkgo will treat my information in accordance with Ginkgo's Privacy Policy. By submitting this job application, I am acknowledging that I have reviewed and agree to Ginkgo's Privacy Policy as well as the privacy policies of the third-party service providers used by Ginkgo's associated with the application process.
Top Skills
Ginkgo Bioworks Boston, Massachusetts, USA Office
27 Drydock Ave, 8th floor, Boston, MA, United States, 02210
Similar Jobs
What you need to know about the Boston Tech Scene
Key Facts About Boston Tech
- Number of Tech Workers: 269,000; 9.4% of overall workforce (2024 CompTIA survey)
- Major Tech Employers: Thermo Fisher Scientific, Toast, Klaviyo, HubSpot, DraftKings
- Key Industries: Artificial intelligence, biotechnology, robotics, software, aerospace
- Funding Landscape: $15.7 billion in venture capital funding in 2024 (Pitchbook)
- Notable Investors: Summit Partners, Volition Capital, Bain Capital Ventures, MassVentures, Highland Capital Partners
- Research Centers and Universities: MIT, Harvard University, Boston College, Tufts University, Boston University, Northeastern University, Smithsonian Astrophysical Observatory, National Bureau of Economic Research, Broad Institute, Lowell Center for Space Science & Technology, National Emerging Infectious Diseases Laboratories
